5-year overall survival

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%